<DOC>
	<DOCNO>NCT00357305</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together cytarabine etoposide treat patient relapsed refractory acute leukemia myelodysplastic syndrome myeloproliferative disorder . Vorinostat may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cytarabine etoposide , work different way stop growth cancer cell , either kill cell stop divide . Giving vorinostat together cytarabine etoposide may kill cancer cell .</brief_summary>
	<brief_title>Vorinostat , Cytarabine , Etoposide Treating Patients With Relapsed and/or Refractory Acute Leukemia Myelodysplastic Syndromes Myeloproliferative Disorders</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility , tolerability , toxicity , term maximum tolerate dose ( MTD ) , sequential combination vorinostat ( SAHA ) follow cytarabine etoposide patient relapse and/or refractory acute leukemia transform myelodysplastic syndrome myeloproliferative disorder . II . Determine whether addition SAHA cytarabine etoposide chemotherapy improve outcome , term complete response rate , duration response , overall survival , patient . III . Determine effect SAHA induction tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL ) -death receptor DR4 DR5 pro-apoptotic mediator patient-derived cancer cell ( leukemia blast cell ) somatic cell ( buccal mucosa cell , use pre-SAHA SAHA treatment sample ) . IV . Determine ability SAHA block leukemia blast cell G1 phase cell cycle ( leukemia blast cell , use pre-SAHA SAHA treatment sample ) . V. Determine effect SAHA expression P-glycoprotein/MDR1/ABCB1 , breast cancer resistance protein ( BCRP/ABCG2 ) , use functional mRNA/protein assay transporter ( leukemia blast cell , use pre-SAHA SAHA treatment sample ) . OUTLINE : This dose-escalation study vorinostat ( SAHA ) . Patients receive oral SAHA two three time daily day 1-7 cytarabine intravenously ( IV ) 3 hour twice daily etoposide IV 1 hour daily day 11-14 . Treatment repeat approximately every 6-7 week 3 course absence disease progression unacceptable toxicity . Patients achieve complete response 1 course therapy may receive 1 2 course therapy . Patients achieve partial response 1 course therapy may receive 1 course therapy . Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 10 patient treat dose . Blood , buccal cell , bone marrow sample collect prior treatment . Samples use pharmacokinetic pharmacodynamic study , protein expression study , gene expression profile . After completion study treatment , patient follow within 30 day .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis 1 following : Relapsed refractory acute myeloid leukemia ( AML ) Patients acute promyelocytic leukemia ( 15 ; 17 ) must fail prior tretinoin arsenic trioxidecontaining regimen Must refractory agent absence durable hematologic response OR relapse complete response duration &lt; 6 month Relapsed refractory acute lymphoblastic leukemia Chronic myelogenous leukemia accelerate blastic phase Must refractory treatment imatinib mesylate dasatinib Disease progression despite continued treatment imatinib mesylate dasatinib Patients accelerate blastic phase eligible unable tolerate imatinib mesylate provide disease progress dasatinib unable tolerate dasatinib AML arise set underlying myelodysplastic syndrome ( MDS ) and/or myeloproliferative disorder ( MPD ) Secondary therapyrelated AML No active CNS leukemia Leukostasis OR leukemic blast count &gt; 50,000/mm³ allow provide patient treat emergency leukapheresis hydroxyurea reduce leukemic blast count &lt; 30,000/mm³ ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history cytarabinerelated neurotoxicity No history allergic reaction attribute compound similar chemical biologic composition vorinostat ( SAHA ) agent use study No uncontrolled illness , include , limited , follow : Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude compliance study requirement Infection allow provide patient receive active treatment No HIV positivity See Disease Characteristics Recovered prior therapy Persistent alopecia , fingernail discoloration , hematologic abnormality ( primarily relate underlying disease ) &gt; 4 week last course chemotherapy radiotherapy exclude patient At least 2 week since prior valproic acid histone deacetylase inhibitor No 3 prior course induction/reinduction chemotherapy , include induction consolidation therapy induction therapy bone marrow transplantation similar procedure Prior lowdose azacitidine , growth factor , cytokine , thalidomide , interferon , imatinib mesylate treatment precede MDS/MPD count prior induction/reinduction therapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas [ e.g. , carmustine ] mitomycin C ) radiotherapy At least 24 hour since prior hydroxyurea At least 2 week since prior imatinib mesylate , hematopoietic growth factor , biological agent At least 4 week since prior autologous stem cell transplantation Prior allogeneic stem cell transplantation allow follow criterion meet : At least 90 day since prior transplant No evidence graftvshost disease At least 2 week since prior immunosuppressive therapy No concurrent anticancer agent therapies No concurrent investigational agent Concurrent hydroxyurea leukapheresis allow day 110 study treatment control rise leukemic blast ( blast &gt; 30,000/mm³ ) leukostasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>